-+ 0.00%
-+ 0.00%
-+ 0.00%

Lisata Therapeutics, Kuva Labs cut tender offer price to $4, boost CVR payout to up to $3

PUBT·05/29/2026 20:51:10
Listen to the news
Lisata Therapeutics, Kuva Labs cut tender offer price to $4, boost CVR payout to up to $3
  • Kuva Labs agreed to cut its cash tender offer for Lisata Therapeutics to USD 4 per share from USD 5.
  • Revised consideration includes one non-tradable CVR with up to USD 3 in milestone payments, replacing a USD 1 CVR.
  • CVR pays USD 1.25 on enrollment completion or near-completion in a Phase 2a glioblastoma study, due no earlier than Dec. 15, 2026.
  • CVR pays USD 1.75 on an NDA filing or acceptance for review for certepetide, payable 45 days after the milestone.
  • Tender offer start moved to June 1, 2026; outside date extended to July 6, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-023336), on May 29, 2026, and is solely responsible for the information contained therein.